Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • LIFE Offering
    • SEDAR+
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Aug 08, 2025 7:54pm EDT

XORTX Completes USD $114,500 Private Placement

Aug 07, 2025 7:00am EDT

XORTX Provides Corporate Update and Planned Activities for 2025 / 2026

Jul 31, 2025 7:00am EDT

XORTX Announces USD $114,500 Private Placement

Jul 22, 2025 7:59pm EDT

XORTX Completes Non-Brokered Private Placement of Units

Jun 26, 2025 7:00am EDT

XORTX Announces USD $925,000 Private Placement

May 19, 2025 7:00am EDT

XORTX Announces USD $3 Million Offering

Apr 30, 2025 7:00am EDT

XORTX Provides Update on FDA Type B Meeting Request

Apr 28, 2025 7:00am EDT

XORTX Announces Grant of European Patent

Apr 17, 2025 7:45pm EDT

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Mar 19, 2025 7:00am EDT

XORTX Announces Update for Discussion with the FDA

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …18
  • arrow_forward
rss_feed News RSS
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap